Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am interested in this company, the web site doesn't open to me, is it correct?
Hello everybody!
What a point: Blood pressure monitor market forecast to exceed $2.6 billion by 2020
wow this will be wonderful
solid and not finished yet. we want more!
LXGTF simplify and save lifes! Current Standards are Complicated and Expensive
• Gold standard - ULTRASOUND
• Measurement directly views arterial diameter
changes
• Only at specialized diagnostic centers
• Requires trained ultrasonographer
• Expensive capital equipment needed
• Alternative method - ENDOPAT
• Measurement uses a fingertip blood oxygen
sensor and laptop computer.
• Only at specialized diagnostic centers
• Requires trained technician
Currently only used in specialized research centers by highly trained staff
REAL FACTS!: Undiagnosed Cardiovascular Disease Is a Killer
• 1 in 3 deaths annually are caused by heart disease
and stroke.
• 1.5 million people suffer heart attacks annually in
the U.S.
• Nearly 1/3 of the deaths could be prevented
through proactive changes in lifestyle habits.
• Often the FIRST SYMPTOM of coronary artery
disease is a heart attack.
Check THE LXGTF Management Team: https://lexingtonbiosciences.com/company/management/
"WOW! this Dr. Maltz on the management team is super smart! : https://lexingtonbiosciences.com/company/management/
LXGTF Corporate Presentation: https://lexingtonbiosciences.com/wp-content/uploads/2017/10/Lexington-Website-Presentation.pdf
GREAT LXGTF VIDEO: https://vimeo.com/183611304
Start your DD here, LXGTF website: https://lexingtonbiosciences.com/
Lt's jump on the glory train! New day, new week, new victories!
Good morning everybody!!!
this is good end
Good closure, next week will be exiting
full package of blessings
Thank you max
ok thank you, yes was not today news
what that means?
still good, let's see the power hour developments
About Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF)
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person's vascular endothelium - the vital innermost lining of a person's cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in portfolio of multiple pending and issued patents licensed to the company. By taking delivery of the clinical trial ready HeartSentry units the company will commence studies as soon as possible. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person's cardiovascular health. Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit:
https://lexingtonbiosciences.com/.
Eric Willis
CEO & Director
INDUSTRY WORTH BILLIONS HAVE YOU SOW IT?
http://techstockinsider.com/the-wearable-tech-thats-disrupting-an-industry-worth-billions/
Values
Excellence. Create a challenging and dynamic environment with excellence as an achievable goal in all we do.
Progress. Our work is focused on improving the lives of others. We believe the tools to achieve a healthy society must improve and we intend to be a positive part of this ongoing evolution.
Innovate. Consistently deliver exceptional products, identify clearly unmet needs and solve them, and always seek the potential for ever better results.
Trust. Engender trust by always performing in an ethical and professional manner.
Respect. Treat our stakeholders, investors, vendors, suppliers and future customers as we would like to be treated ourselves.
Mission Statement
Lexington Biosciences seeks to create and promote a suite of meaningful data centered cardiovascular monitoring technologies to provide patients relevant metrics so that they can lead longer and healthier lives.
LXGTF Engages Clinical Research Organization!!
“WITH TODAY’S (11/30/17) ANNOUNCEMENT (LXGTF)’S PLANS ARE NOW ADVANCING TO INITIATE COMMENCEMENT OF A PILOT CLINICAL RESEARCH STUDY DESIGNED TO BEGIN GATHERING THE FOUNDATIONAL DATASET AIMED AT SUPPORTING FDA CLEARANCE.”
VANCOUVER, BC–(Marketwired – Nov 30, 2017) – Lexington Biosciences, Inc. ( CSE : LNB ) ( OTCQB : LXGTF ) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce the engagement of San Francisco Bay Area-based Diablo Clinical Research to conduct its upcoming HeartSentry pilot clinical studies.
Lexington recently announced delivery of its initial order of HeartSentry devices slated for clinical trials. With today’s announcement, plans are now advancing to initiate commencement of a pilot clinical research study designed to begin gathering the foundational dataset aimed at supporting FDA clearance.
Diablo Clinical Research has specialized in clinical research for over 22 years. Founded in 1995, Diablo’s team has conducted over 600 studies with thousands of patients and in the process, has assembled a database comprising over 15,000 patients who have either completed a study, are currently enrolled in a study, or have expressed interest in future clinical study participation. The firm has 4 MDs on staff with specialties in endocrinology, internal medicine, and cardiology. Find out more at: www.diabloclinical.com.
Dr. Geoff Tison, Cardiologist and Assistant Professor in the Division of Cardiology at the University of California San Francisco and Medical Advisor to the company comments, “After a fifteen-year research process, I am excited to see Lexington beginning their clinical research efforts in order to gather clinical study data for the HeartSentry device. With the recent publication of the more stringent American Heart Association hypertension management guidelines, there is increased awareness of the need to more closely monitor patients for cardiovascular risk factors, which HeartSentry is well positioned to do.”
Lexington’s President Eric Willis comments, “After nine months of concerted effort by our design and production team, the arrival of our first human-use HeartSentry devices allows us to accelerate our plans to move ahead with our pilot study. Diablo Clinical Research is a proven and respected establishment with the capability to launch our research program efficiently and cost-effectively. They have been extremely helpful in the determination process which has led to today’s announcement. We are excited to begin this next step of our development phase, and look forward to sharing quantifiable results in the near future.
http://techstockinsider.com/lexington-biosciences-lxgtf-lnb-engages-clinical-research-organization/?utm_medium=Social&utm_source=TSI_Social_Link&utm_campaign=TSI_Social_1130
Going Higher!
Looks like we going forward finaly
.43 green, GOOD START!
HAVE YOU SEE IT??? LXGTF is potential 50 Billion Dollar Industry Penny Stock to Watch!
Read More here:
https://t.co/4nL5f2LtnQ
STEP BEFORE OTHERS! Endothelial function measurement predicts when arteries are vulnerable to developing atherosclerosis
LXGTF VS FACTS wich ARE: Undiagnosed Cardiovascular Disease Is a Killer
• 1 in 3 deaths annually are caused by heart disease
and stroke.
• 1.5 million people suffer heart attacks annually in
the U.S.
• Nearly 1/3 of the deaths could be prevented
through proactive changes in lifestyle habits.
• Often the FIRST SYMPTOM of coronary artery
disease is a heart attack.
Great LXGTF Management Team:
https://lexingtonbiosciences.com/company/management/
Well explained! LXGTF Article by Jonathan Maltz, "What is Endothelial Function..." :
https://lexingtonbiosciences.com/news/endothelial-function-important-health/
Watch the LXGTF Corporate Profile: https://lexingtonbiosciences.com/investors/corporate-profile/
Good morning Italian, good to see you!
Good morning FVRD!
Good morning :)
HeartSentry Technology rectifies this alarming situation:
Quote:
The First Sign of Cardiovascular Disease is Often an Unannounced Heart Attack!
• Current first line cardiovascular health
diagnostics are insensitive at measuring
heart disease development and
progression
• Specialized cardiovascular diagnostics
are highly invasive and expensive and
generally catch cardiovascular disease
AFTER it’s developed
my connection is not good
Agreed!